5-溴-2-氯-N-(丙-2-烯-1-基)嘧啶-4-胺 | 959799-08-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-溴-2-氯-N-(丙-2-烯-1-基)嘧啶-4-胺
• 英文名称: Allyl-(5-bromo-2-chloro-pyrimidin-4-yl)-amine
• 英文别名: 5-bromo-2-chloro-N-(prop-2-en-1-yl)pyrimidin-4-amine；5-bromo-2-chloro-N-prop-2-enylpyrimidin-4-amine
• CAS: 959799-08-7
• 化学式: C₇H₇BrClN₃
• 分子量: 248.51
• InChiKey: QOZHHZIFJBEYDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-溴-2-氯-N-(丙-2-烯-1-基)嘧啶-4-胺 在 palladium diacetate 三乙胺 、 三苯基膦 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以40%的产率得到2-氯-5-甲基-7h-吡咯并[2,3-d]嘧啶
  参考文献：
  名称：

  Pyrrolopyrimidine Compounds and Their Uses

  摘要：

  本申请描述了对治疗、预防及/或改善疾病有用的有机化合物，特别是描述了抑制蛋白激酶的吡咯并嘧啶化合物及其衍生物。这些有机化合物在治疗增殖性疾病中是有用的。

  公开号：

  US20090318441A1
• 作为产物：
  描述：

  5-溴-2,4-二氯嘧啶 、 丙烯胺 在 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 生成 5-溴-2-氯-N-(丙-2-烯-1-基)嘧啶-4-胺
  参考文献：
  名称：

  Pyrrolopyrimidine Compounds and Their Uses

  摘要：

  本申请描述了对治疗、预防及/或改善疾病有用的有机化合物，特别是描述了抑制蛋白激酶的吡咯并嘧啶化合物及其衍生物。这些有机化合物在治疗增殖性疾病中是有用的。

  公开号：

  US20090318441A1

文献信息

• [EN] COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS<br/>[FR] COMPOSÉS PERMETTANT DE RÉGULER LES VOIES FAK ET/OU SRC
  申请人：ASANA BIOSCIENCES LLC

  公开号：WO2015038417A1

  公开（公告）日：2015-03-19

  The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新颖的可选择替代的融合吡啶和嘧啶双环化合物及其药用可接受盐。还提供了制备这些化合物的方法。通过向受试者投予一种或多种化合物的治疗有效量，这些化合物在共调节FAK和/或Src活性方面具有用处。通过这样做，这些化合物在治疗与FAK和/或Src途径失调相关的疾病方面具有有效性。这些化合物作为双重FAK和/或Src抑制剂表现出优势。可以使用这些化合物治疗各种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。
• 3-(Heteroaryal) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
  申请人：——

  公开号：US20020052375A1

  公开（公告）日：2002-05-02

  Disclosed are certain 3-(heteroaryl)alanine derivatives which bind VLA-4 and inhibit leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

  本发明涉及某些3-(杂环芳基)丙氨酸衍生物，其与VLA-4结合并抑制由VLA-4介导的白细胞粘附。这些化合物可用于治疗哺乳动物患者（例如人类）的炎症性疾病，如哮喘、阿尔茨海默病、动脉粥样硬化、艾滋病痴呆、糖尿病、炎性肠病、类风湿性关节炎、组织移植、肿瘤转移和心肌缺血。这些化合物还可用于治疗多发性硬化等炎症性脑部疾病。
• 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
  申请人：Elan Pharmaceuticals, Inc.

  公开号：US20040266763A1

  公开（公告）日：2004-12-30

  Disclosed are certain 3-(heteroaryl)alanine derivatives which bind VLA-4 and inhibit leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

  本发明涉及某些3-(杂环芳基)丙氨酸衍生物，其与VLA-4结合并抑制VLA-4介导的白细胞粘附。这些化合物在哺乳动物患者，例如人类，如哮喘，阿尔茨海默病，动脉粥样硬化，艾滋病痴呆，糖尿病，炎症性肠病，类风湿性关节炎，组织移植，肿瘤转移和心肌缺血等炎症性疾病的治疗中有用。这些化合物还可以用于治疗多发性硬化等炎症性脑部疾病。
• Steroid sparing agents and methods of using same
  申请人：Lieberburg Ivan

  公开号：US20060004019A1

  公开（公告）日：2006-01-05

  This invention relates generally to methods of treatment of inflammatory bowel diseases (IBD), asthma, multiple schlerosis (MS), rheumatoid arthritis (RA), graft vs. host disease (GVHD), host vs. graft disease, and various spondyloarthropathies, comprising administering a steroid sparing immunoglobulin or small molecule composition to a patient in need thereof. The invention also relates generally to combination therapies for the treatment of these conditions.

  本发明涉及治疗炎症性肠病(IBD)、哮喘、多发性硬化症(MS)、类风湿性关节炎(RA)、移植物抗宿主病(GVHD)、宿主抗移植物病以及各种脊柱关节病的方法，包括向需要治疗的患者投予一种节省类固醇的免疫球蛋白或小分子组合物。本发明还涉及治疗这些疾病的联合疗法。
• Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
  申请人：——

  公开号：US20030125324A1

  公开（公告）日：2003-07-03

  Disclosed are compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

  本发明涉及一种可以结合VLA-4的化合物。其中一些化合物还可以抑制白细胞粘附，特别是通过VLA-4介导的白细胞粘附。这些化合物在哺乳动物患者（例如人类）的炎症性疾病治疗中非常有用，例如哮喘、阿尔茨海默病、动脉硬化、艾滋病痴呆、糖尿病、炎症性肠病、类风湿性关节炎、组织移植、肿瘤转移和心肌缺血。这些化合物还可以用于治疗多发性硬化等炎症性脑部疾病。